Sabanayagam, C., Yip, W., Ting, D. S. W., Tan, G. & Wong, T. Y. Ten emerging trends in the epidemiology of diabetic retinopathy. Ophthalmic Epidemiol. 23, 209–222 (2016).
Wong, T. Y. et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 32, 2307–2313 (2009).
Article PubMed PubMed Central Google Scholar
Li, H. et al. Current research and future strategies for the management of vision-threatening diabetic retinopathy. Asia Pac. J. Ophthalmol. 13, 100109 (2024).
Wong, T. Y. & Tan, T.-E. The diabetic retinopathy ‘pandemic’ and evolving global strategies: the 2023 friedenwald lecture. Invest. Ophthalmol. Vis. Sci. 64, 47 (2023).
Article PubMed PubMed Central Google Scholar
Ting, D. S. W., Cheung, G. C. M. & Wong, T. Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review: global burden of diabetic eye diseases. Clin. Exp. Ophthalmol. 44, 260–277 (2016).
Gardner, T. W., Antonetti, D. A., Barber, A. J., LaNoue, K. F. & Levison, S. W. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 47, S253–S262 (2002).
Wong, T. Y., Cheung, C. M., Larsen, M., Sharma, S. & Simó, R. Diabetic retinopathy. Nat. Rev. Dis. Primers 2, 16012 (2016).
Abramoff, M. D. et al. Approach for a clinically useful comprehensive classification of vascular and neural aspects of diabetic retinal disease. Invest. Ophthalmol. Vis. Sci. 59, 519–527 (2018).
Article CAS PubMed PubMed Central Google Scholar
Sun, J. K. et al. Updating the staging system for diabetic retinal disease. Ophthalmology 128, 490–493 (2021). The manuscript provides the evidence why a new staging system for diabetic retinopathy is warranted.
Levine, S. R., Sapieha, P., Dutta, S., Sun, J. K. & Gardner, T. W. It is time for a moonshot to find ‘cures’ for diabetic retinal disease. Prog. Retin. Eye Res. 90, 101051 (2022).
Article CAS PubMed Google Scholar
Tan, T.-E. et al. Imaging modalities for assessing the vascular component of diabetic retinal disease: review and consensus for an updated staging system. Ophthalmol. Sci. 4, 100449 (2024). This manuscript highlights the current evidence and gaps in imaging microvascular changes in diabetic retinopathy.
Glassman, A. R. et al. Visual function measurements in eyes with diabetic retinopathy: an expert opinion on available measures. Ophthalmol. Sci. 4, 100519 (2024). This narrative review on visual function demonstrates the need to integrate visual function measures in future diabetic retinopathy classification.
Article PubMed PubMed Central Google Scholar
Vujosevic, S., Chew, E., Labriola, L., Sivaprasad, S. & Lamoureux, E. Measuring quality of life in diabetic retinal disease: a narrative review of available patient-reported outcome measures. Ophthalmol. Sci. 4, 100378 (2024). This manuscript highlights the lack of PROMs that can be used in diabetic retinopathy clinical trials and practice and the need to develop more appropriate measures.
Hartnett, M. E. et al. Rationale of basic and cellular mechanisms considered in updating the staging system for diabetic retinal disease. Ophthalmol. Sci. 4, 100521 (2024). This manuscript provides a summary of mechanisms of diabetic retinal disease to inform future classification of diabetic retinal disease.
Article PubMed PubMed Central Google Scholar
Channa, R. et al. A new approach to staging diabetic eye disease: staging of diabetic retinal neurodegeneration and diabetic macular edema. Ophthalmol. Sci. 4, 100420 (2024). This review of current evidence of neurodegeneration in diabetic retinopathy highlights the evidence gaps especially in early disease.
Nair, P., Aiello, L. P., Gardner, T. W., Jampol, L. M. & Ferris, F. L. III Report from the NEI/FDA diabetic retinopathy clinical trial design and endpoints workshop. Invest. Ophthalmol. Vis. Sci. 57, 5127–5142 (2016).
Article PubMed PubMed Central Google Scholar
Nugawela, M. D. et al. Development and validation of predictive risk models for sight threatening diabetic retinopathy in patients with type 2 diabetes to be applied as triage tools in resource limited settings. eClinicalMedicine 51, 101578 (2022).
Article PubMed PubMed Central Google Scholar
Guo, H. et al. Scoring and validation of a simple model for predicting diabetic retinopathy in patients with type 2 diabetes based on a meta-analysis approach of 21 cohorts. Ann. Med. 56, 2413920 (2024).
Article PubMed PubMed Central Google Scholar
Vujosevic, S., Limoli, C. & Nucci, P. Novel artificial intelligence for diabetic retinopathy and diabetic macular edema: what is new in 2024? Curr. Opin. Ophthalmol. 35, 472–479 (2024).
Article PubMed PubMed Central Google Scholar
Tan, T.-E. & Wong, T. Y. Diabetic retinopathy: looking forward to 2030. Front. Endocrinol. 13, 1077669 (2022).
Li, J. et al. Integrated image-based deep learning and language models for primary diabetes care. Nat. Med. 30, 2886–2896 (2024).
Article CAS PubMed PubMed Central Google Scholar
Arabi, A., Tadayoni, R., Ahmadieh, H., Shahraki, T. & Nikkhah, H. Update on management of non-proliferative diabetic retinopathy without diabetic macular edema; is there a paradigm shift? J. Ophthalmic Vis. Res. 17, 108-117 (2022).
Article PubMed PubMed Central Google Scholar
Bahr, T. A. & Bakri, S. J. Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy. Life 13, 1098 (2023).
Article CAS PubMed PubMed Central Google Scholar
Kim, E. J. et al. Treatment of diabetic macular edema. Curr. Diab. Rep. 19, 68 (2019).
Somani, S. et al. Characteristics and treatment patterns of patients with diabetic macular edema non-responsive to anti-vascular endothelial growth factor treatment in Ontario, Canada. Clin. Ophthalmol. 17, 2013–2025 (2023).
Article CAS PubMed PubMed Central Google Scholar
Mandava, N. K. et al. Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema. Curr. Opin. Ophthalmol. 35, 197–204 (2024).
Bressler, N. M. et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: a review. Surv. Ophthalmol. 69, 521–538 (2024). As we pave forward to ensure diabetic retinopathy treatment is available and equitable to all, this review provides a comprehensive understanding on biosimilars and their use in ophthalmology.
Sun, H. et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).
No authors listed. Diabetes is ‘a pandemic of unprecedented magnitude’ now affecting one in 10 adults worldwide. Diabetes Res. Clin. Pract. 181, 109133 (2021).
Unnikrishnan, R., Pradeepa, R., Joshi, S. R. & Mohan, V. Type 2 diabetes: demystifying the global epidemic. Diabetes 66, 1432–1442 (2017).
Article CAS PubMed Google Scholar
Teo, Z. L. et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 128, 1580–1591 (2021). This systematic review provides the latest and projected figures on the prevalence of diabetic retinopathy to demonstrate the global burden of the disease.
Gurudas, S. et al. National prevalence of vision impairment and blindness and associated risk factors in adults aged 40 years and older with known or undiagnosed diabetes: results from the SMART-India cross-sectional study. Lancet Glob. Health 12, e838–e847 (2024).
Article CAS PubMed Google Scholar
Li, X., Tan, T.-E., Wong, T. Y. & Sun, X. Diabetic retinopathy in China: epidemiology, screening and treatment trends-a review. Clin. Exp. Ophthalmol. 51, 607–626 (2023).
Comments (0)